Abstract: The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, deletions and replacements of one or more amino acids as compared to a wild-type amino acid sequence, and has enhanced shear resistance.

Abstract: Provided are a CD19-targeting chimeric antigen receptor and use thereof. Further provided are a CD19-targeting chimeric antigen receptor, a corresponding nucleic acid molecule, a vector, an immune effector cell, a preparation method therefor, a product thereof, a pharmaceutical composition, a therapeutic use, a pharmaceutical use, and a tumor or cancer treatment method.

Abstract: The present invention relates to an enhanced chimeric antigen receptor and use thereof, including a nucleic acid molecule for encoding a chimeric antigen receptor containing an NKG2D transmembrane region, a corresponding chimeric antigen receptor, a carrier, an immune effector cell, a preparation method and a product thereof, a pharmaceutical composition, pharmaceutical use, and a tumor or cancer treatment method. The present invention has the advantages of high CAR expression efficiency, rapid NK cell proliferation, strong killing ability against tumor cells, high specificity, long duration of killing effect, and the like.

Abstract: Provided is a multispecific antigen binding protein. Provided is a multispecific antigen binding protein comprising one or more amino acid substitutions at CH1 and CL, a composition comprising same, a preparation method therefor, and a medical use thereof. The specific antigen binding protein effectively reduces the mismatching of light chains.

Abstract: The present disclosure relates to anti-CD25 antibodies, antigen-binding fragments thereof, and medical uses thereof. Specifically, the present disclosure relates to anti-CD25 antibodies and their use for preparing anti-tumor drugs.